title: Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).
abstract: Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 years. Many elderly patients are also vulnerable because of comorbidities that complicate the management of MM. The prevalence of MM is expected to rise over time because of an aging population. Most elderly patients with MM are ineligible for autologous transplantation, and the standard treatment has, until recently, been melphalan plus prednisone. The introduction of novel agents, such as thalidomide, bortezomib, and lenalidomide, has improved outcomes; however, elderly patients with MM are more susceptible to side effects and are often unable to tolerate full drug doses. For these patients, lower-dose-intensity regimens improve the safety profile and thus optimize treatment outcome. Further research into the best treatment strategies for vulnerable elderly patients is urgently needed. Appropriate screening for vulnerability and an assessment of cardiac, pulmonary, renal, hepatic, and neurologic functions, as well as age > 75 years, at the start of therapy allows treatment strategies to be individualized and drug doses to be tailored to improve tolerability and optimize efficacy. Similarly, occurrence of serious nonhematologic adverse events during treatment should be carefully taken into account to adjust doses and optimize outcomes.
authors.affiliation: Division of Hematology, University of Torino, Azinda Ospedaliero-Universitaria S. Giovanni Battista, Torino, Italy. appalumbo@yahoo.com
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
authors.forename: Sara
authors.initials: S
authors.lastname: Bringhen
authors.forename: Heinz
authors.initials: H
authors.lastname: Ludwig
authors.forename: Meletios A
authors.initials: MA
authors.lastname: Dimopoulos
authors.forename: Joan
authors.initials: J
authors.lastname: Bladé
authors.forename: Maria V
authors.initials: MV
authors.lastname: Mateos
authors.forename: Laura
authors.initials: L
authors.lastname: Rosiñol
authors.forename: Mario
authors.initials: M
authors.lastname: Boccadoro
authors.forename: Michele
authors.initials: M
authors.lastname: Cavo
authors.forename: Henk
authors.initials: H
authors.lastname: Lokhorst
authors.forename: Sonja
authors.initials: S
authors.lastname: Zweegman
authors.forename: Evangelos
authors.initials: E
authors.lastname: Terpos
authors.forename: Faith
authors.initials: F
authors.lastname: Davies
authors.forename: Christoph
authors.initials: C
authors.lastname: Driessen
authors.forename: Peter
authors.initials: P
authors.lastname: Gimsing
authors.forename: Martin
authors.initials: M
authors.lastname: Gramatzki
authors.forename: Roman
authors.initials: R
authors.lastname: Hàjek
authors.forename: Hans E
authors.initials: HE
authors.lastname: Johnsen
authors.forename: Fernando
authors.initials: F
authors.lastname: Leal Da Costa
authors.forename: Orhan
authors.initials: O
authors.lastname: Sezer
authors.forename: Andrew
authors.initials: A
authors.lastname: Spencer
authors.forename: Meral
authors.initials: M
authors.lastname: Beksac
authors.forename: Gareth
authors.initials: G
authors.lastname: Morgan
authors.forename: Hermann
authors.initials: H
authors.lastname: Einsele
authors.forename: Jesus F
authors.initials: JF
authors.lastname: San Miguel
authors.forename: Pieter
authors.initials: P
authors.lastname: Sonneveld
mesh_terms: D000367:Age Factors; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D019058:Community Networks; D005060:Europe; D016330:Frail Elderly; D006801:Humans; D009101:Multiple Myeloma / Q000453:epidemiology / Q000628:therapy*; D057285:Precision Medicine / Q000379:methods*; D035862:Vulnerable Populations / Q000706:statistics & numerical data